SCHEMBL17744250

SCHEMBL17744250

CC1CNCCN1c1nc2cc(Cl)cc(-c3ncccc3F)c2o1

nearest known ligand 0.37

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.37
▸ HTR2C P28335 5/20 0.36
▸ HTR2A P28223 2/20 0.36
▸ USP7 Q93009 1/20 0.35
▸ ROCK2 O75116 1/20 0.35
▸ WEE1 P30291 3/20 0.34
▸ HTR2B P41595 2/20 0.34
▸ ALK Q9UM73 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ MET P08581 1/20 0.34
▸ LATS1 O95835 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16391321 1.00 TRPV1 (0.37) TRPV1HTR2CHTR2AUSP7ROCK2
SCHEMBL16391325 0.90 USP7 (0.39) TRPV1HTR2CHTR2AUSP7WEE1
SCHEMBL17744225 0.90 USP7 (0.39) TRPV1HTR2CHTR2AUSP7WEE1
SCHEMBL17744597 0.88 CCNT1 (0.37) TRPV1HTR2CHTR2AUSP7ALK
SCHEMBL16391295 0.88 CCNT1 (0.37) TRPV1HTR2CHTR2AUSP7ALK
SCHEMBL16391293 0.87 HTR2C (0.35) TRPV1HTR2CHTR2AUSP7WEE1
SCHEMBL17744269 0.87 HTR2C (0.35) TRPV1HTR2CHTR2AUSP7WEE1
SCHEMBL17744236 0.86 HTR2C (0.38) TRPV1HTR2CUSP7ROCK2WEE1
SCHEMBL16391457 0.86 HTR2C (0.38) TRPV1HTR2CUSP7ROCK2WEE1
SCHEMBL16391595 0.84 HTR2C (0.39) TRPV1HTR2CHTR2AUSP7WEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020718-B1 NOVEL PDE4 INHIBITOR MEIJI SEIKA PHARMA CO LTD (JP) 2018-12-26 — — EP claimed
US-9890142-B2 PDE4 inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-02-13 — — US claimed
US-9850235-B2 — — 2017-12-26 — — US claimed
US-20160159783-A1 PDE4 Inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-06-09 — — US claimed
EP-3020718-A1 NOVEL PDE4 INHIBITOR Meiji Seika Pharma Co., Ltd. (JP) 2016-05-18 — — EP claimed
EP-3020718-B1 NOVEL PDE4 INHIBITOR MEIJI SEIKA PHARMA CO LTD (JP) 2018-12-26 — — EP disclosed
US-9890142-B2 PDE4 inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-02-13 — — US disclosed
US-9850235-B2 — — 2017-12-26 — — US disclosed
US-20160159783-A1 PDE4 Inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-06-09 — — US disclosed
EP-3020718-A1 NOVEL PDE4 INHIBITOR Meiji Seika Pharma Co., Ltd. (JP) 2016-05-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159783-A1 PDE4 Inhibitor PDE4A, PDE4B, PDE3B TRPV1 3440/4885HTR2C 3334/4885HTR2A 3249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback